Patients with Rheumatoid Arthritis Undergoing Surgery: How Should We Deal with Antirheumatic Treatment?

Pieringer, Herwig; Stuby, U; Biesenbach, Georg

doi:10.1016/j.semarthrit.2006.10.003

Cited by 107 publications

(81 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These cytokine-specific inhibitors are a new class of medications, having only been approved for use in humans within the past 10 years. 47,48 Seven agents that antagonize specific cytokines are currently approved for use in human patients: infliximab, adalimumab, etanercept, golimumab, and certolizumab-pegol inhibit TNF-a, whereas anakinra and tocilizumab antagonize IL-1 and IL-6, respectively. 49 Only a small number of studies have reported the effects of these agents on bone healing, and the results have been inconclusive.…”

Section: Cytokine-specific Antagonistsmentioning

confidence: 99%

Harnessing and Modulating Inflammation in Strategies for Bone Regeneration

Mountziaris

Spicer

Kasper

et al. 2011

Tissue Engineering Part B: Reviews

191

201

View full text Add to dashboard Cite

Section: Cytokine-specific Antagonistsmentioning

confidence: 99%

Harnessing and Modulating Inflammation in Strategies for Bone Regeneration

Mountziaris

Spicer

Kasper

et al. 2011

Tissue Engineering Part B: Reviews

191

201

View full text Add to dashboard Cite

“…I. Perioperative Care -Understanding potential perioperative risks in patients with RA Patients with RA are commonly treated with immunosuppressive medications including corticosteroids, methotrexate (MTX), and/or biologic DMARD, which may increase their risk of perioperative infections or affect wound healing. Stopping therapy, however, may result in a flare and impede recovery from surgery 10,11,12 . The balance of these risks needs to be considered when deciding if treatment should be suspended in the perioperative period, and if so, when therapy should be withheld and restarted.…”

Section: Recommendationsmentioning

confidence: 99%

Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety

Bombardier¹,

Hazlewood²,

Akhavan³

et al. 2012

J Rheumatol

124

147

View full text Add to dashboard Cite

ABSTRACT. Objective. The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of rheumatoid arthritis (RA) with traditional and biologic disease-modifying antirheumatic drugs (DMARD) in 2 parts. Part II, focusing on specific safety aspects of treatment with traditional and biologic DMARD in patients with RA, is reported here. Methods. Key questions were identified a priori based on results of a national needs-assessment survey. A systematic review of all clinical practice guidelines and consensus statements regarding treatment with traditional and biologic DMARD in patients with RA published between January 2000 and June 2010 was performed in Medline, Embase, and CINAHL databases, and was supplemented with a "grey literature" search including relevant public health guidelines. Systematic reviews of postmarketing surveillance and RA registry studies were performed to update included guideline literature reviews as appropriate. Guideline quality was independently assessed by 2 reviewers. Guideline characteristics, recommendations, and supporting evidence from observational studies and randomized trials were synthesized into evidence tables. The working group voted on recommendations using a modified Delphi technique.Results. Thirteen recommendations addressing perioperative care, screening for latent tuberculosis infection prior to the initiation of biologic DMARD, optimal vaccination practices, and treatment of RA patients with active or a history of malignancy were developed for rheumatologists, other primary prescribers of RA drug therapies, and RA patients. Conclusion. These recommendations were developed based on a synthesis of international RA and public health guidelines, supporting evidence, and expert consensus in the context of the Canadian health system. They are intended to help promote best practices and improve healthcare delivery for persons with RA. (First Release June 15 2012; J Rheumatol 2012;39:1583-602; doi:10.3899 Recommendations provided here are intended to be read in conjunction with the Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis. These recommendations address specific safety questions that were identified a priori and are not intended to cover all safety aspects concerning treatment with traditional and biologic disease modifying antirheumatic drugs (DMARD).Traditional and biologic DMARD have greatly enhanced the care of persons with rheumatoid arthritis (RA); however, potential risks associated with their use need be considered. The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of RA with traditional and biologic DMARD in 2 parts. Part I described the development process of CRA recommendations in detail and included 5 overarching RA care principles along with 26 treatment recommendations 1 . Part II, reported here, focuses on specific safety aspects of treatment with traditional and biologic DMARD in patients with ...

show abstract

“…These selective anticytokine therapies do not impair bone fracture healing in human patients, which likely reflects the low dosages used clinically, since higher dosages increase the risk of severe infections, particularly tuberculosis. 51,52 However, in an in vitro model of bone healing,…”

Section: Cytokine-specific Agentsmentioning

confidence: 99%

Modulation of the Inflammatory Response for Enhanced Bone Tissue Regeneration

Mountziaris¹,

Mikos²

2008

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

Proinflammatory cytokines are infamous for their catabolic effects on tissues and joints in both inflammatory diseases and following the implantation of biomedical devices. However, recent studies indicate that many of these same molecules are critical for triggering tissue regeneration following injury. This review will discuss the role of inflammatory signals in regulating bone regeneration and the impact of both immunomodulatory and antiinflammatory pharmacologic agents on fracture healing, to demonstrate the importance of incorporating rational control of inflammation into the design of tissue engineering strategies.

show abstract

Patients with Rheumatoid Arthritis Undergoing Surgery: How Should We Deal with Antirheumatic Treatment?

Cited by 107 publications

References 81 publications

Harnessing and Modulating Inflammation in Strategies for Bone Regeneration

Harnessing and Modulating Inflammation in Strategies for Bone Regeneration

Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety

Modulation of the Inflammatory Response for Enhanced Bone Tissue Regeneration

Contact Info

Product

Resources

About